Lab21 expands its range of cardiovascular genetic tests with Clinical Data, Inc.

29-Sep-2008 - United Kingdom

Lab21 announced the expansion of its portfolio of genetic tests for inherited cardiac syndromes. Through its existing UK licence with PGxHealth™, a division of Clinical Data, Inc., Lab21 offers exclusive U.K. and Ireland access to the Familion® portfolio of tests for Long QT and Brugada Syndromes and has now added two new assays for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and Hypertrophic Cardiomyopathy (HCM) to its range of tests.

Berwyn Clarke, Lab21 Chief Scientific and Development Officer commented: “We are delighted to expand our relationship with PGxHealth, who we believe is the market leader in the development of advanced genetic tests for inherited cardiac conditions. The addition of CPVT and HCM to the Familion stable substantially assists UK cardiologists in the accurate diagnosis of cardiac disease. By enabling cardiologists to quickly identify a patient’s risk, the most appropriate monitoring, treatment or lifestyle options can be implemented, significantly improving patient health.”

Other news from the department business & finance

Most read news

More news from our other portals